Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Weighted Average and Diluted) (2021 - 2025)

Sunshine Biopharma (SBFM) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.44 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, EPS (Weighted Average and Diluted) rose 78.0% year-over-year to -$0.44, compared with a TTM value of -$2.34 through Mar 2025, up 63.35%, and an annual FY2024 reading of -$7.32, up 97.92% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.44 for Q1 2025 at Sunshine Biopharma, up from -$3.08 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.26 in Q4 2021 and bottomed at -$97.47 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$9.37, with a median of -$0.34 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 6193.06% in 2023, then soared 96.84% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.26 in 2021, then crashed by 706.43% to -$1.55 in 2022, then plummeted by 6193.06% to -$97.47 in 2023, then surged by 96.84% to -$3.08 in 2024, then surged by 85.69% to -$0.44 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SBFM at -$0.44 in Q1 2025, -$3.08 in Q4 2024, and -$2.0 in Q1 2024.